Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why King Digital Entertainment, Intermune, and Pharmacyclics Jumped Today

This morning, it looked as though Monday would be a horrible day for the stock market, as worries about the health of China's economic growth and ongoing turmoil in Ukraine combined to send stocks falling at the open. Slowly but surely, though, stocks clawed their way back to small gains, and King Digital Entertainment (NYSE: KING  ) , Intermune (NASDAQ: ITMN  ) , and Pharmacyclics (NASDAQ: PCYC  ) had some impressive moves higher in their share prices today.

Source: King Digital Entertainment.

King Digital Entertainment gained 8.5% after the maker of Candy Crush Saga got favorable ratings from several analyst firms. The firms pointed to the King Digital's potential to continue monetizing Candy Crush Saga and the company's other game offerings well into the future, with King Digital well-poised to keep profiting as mobile devices get more common not just in the U.S. but worldwide. The analysts' arguments attempt to counter the market's perception that King Digital is too dependent on its primary game, raising fears that it will flare out like other mobile-gaming companies before it. It's important to remember, though, that among the analysts making positive assessments on the stock were the lead underwriters on King Digital's IPO, and while the recommendations are supposed to be independent of the underwriting relationship, you'll want to draw your own conclusions about how much weight you give them.

Intermune rose 7%, adding to its 2% rise on Friday after the biopharmaceutical company impressed investors with its first-quarter earnings report. Intermune's losses were slightly larger than in the year-ago quarter, but sales of the company's idiopathic pulmonary fibrosis treatment Esbriet almost tripled from last year and rose 18% sequentially from the previous quarter. Although Esbriet is available in Europe, Intermune plans to resubmit an application for approval from the Food and Drug Administration in the U.S. after mid-year. If the FDA approves the drug, then Esbriet could launch as early as next spring. Although widening losses are always troubling, the fact that Intermune has demonstrated success with Esbriet is a positive sign for its future.

Pharmacyclics climbed 8%, regaining every bit of the ground it lost last Friday after its own earnings report failed to inspire the same confidence that Intermune's did. The maker of mantle-cell lymphoma treatment Imbruvica saw total sales soar as a result of the drug's approval and milestone payments associated with its success, turning a year-ago loss into a substantial profit. On Friday, investors seemed disappointed by Pharmacyclics' revenue guidance for the full year, which fell far short of what analysts were expecting. But given the demand for promising treatments, investors might well have decided Monday that Pharmacyclics has potential not just in its own right as an independent company but also as a possible takeover candidate.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour. (That's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click here to discover more about this industry-leading stock, and join Buffett in his quest for a veritable landslide of profits!

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2944100, ~/Articles/ArticleHandler.aspx, 9/5/2015 10:26:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 13 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ITMN $0.00 Down +0.00 +0.00%
InterMune CAPS Rating: **
KING $13.69 Up +0.12 +0.88%
King Digital CAPS Rating: *
PCYC $0.00 Down +0.00 +0.00%